With aspirations to contribute to patients’ lives, we aim to deliver Astellas  products to as many patients as possible and achieve strong patient satisfac- tion. For this, we believe that it is crucial to launch a steady stream of new  products and provide proper, high-quality information. We recently launched  Suglat and XTANDI. To ensure that these new drugs are used appropriately, we  will work to provide accurate information to a range of medical professionals,  including doctors. Meanwhile, the Japanese government has begun implementing various  measures to optimize medical expenditures. In addition, society is putting  increasingly stronger demands on companies for compliance. We will respond accurately to these changes in the operating environment,  as we strive to fulfill medical needs by delivering drugs with high added value  to patients. Yukihiko Sato Senior Vice President and President, Sales & Marketing Japan Review of Operations Annual Report 2014 _  Astellas Pharma Inc.  45 Launch of New Products (2013.4–2014.6) *Invoiced price base (¥ billion) 2013.3 J-GAAP 2014.3 2015.3 (Forecast) IFRS J-GAAP IFRS Prescription drug sales in the Japanese market 535.8 ⬇  535.6 515.6 ⬇ 508.3 Hypertension treatment (Long-acting angiotensin II receptor blocker) Micardis 89.6 $_{⬆}$ 97.6 97.6 ⬇ 97.5 Micombi 11.6 $_{⬆}$ 11.8 11.8 Micamlo 15.7 $_{⬆}$ 21.4 21.4 Hypercholesterolemia treatment Lipitor 70.6 ⬇ 62.4 62.4 ⬇ 52.6 Caduet 9.6 $_{⬆}$ 10.7 10.7 Immunosuppressant Prograf 49.4 $_{⬆}$ 50.4 50.4 ⬇ 49.6 Anti-inflammatory agent (Selective COX-2 inhibitor) Celecox 37.4 $_{⬆}$ 44.3 44.3 $_{⬆}$ 45.9 Adult bronchial asthma treatment Symbicort 27.7 $_{⬆}$ 35.6 35.6 $_{⬆}$ 36.3 Vaccines 28.8 $_{⬆}$ 35.0 35.0 $_{⬆}$ 35.7 OAB treatment Vesicare 29.8 $_{⬆}$ 30.7 30.7 ⬇ 24.2 Insomnia treatment Myslee 32.2 ⬇ 28.2 28.2 ⬇ 20.2 Treatment for peptic ulcers and gastritis Gaster 30.2 ⬇ 25.7 25.7 ⬇ 19.5 Treatment for the functional symptoms associated with benign prostatic hyperplasia Harnal 23.0 ⬇ 20.2 20.2 ⬇ 16.0 Schizophrenia treatment Seroquel 28.5 ⬇ 19.6 19.6 ⬇ 12.6 Treatment for osteoporosis Bonoteo 10.7 $_{⬆}$ 14.1 14.1 $_{⬆}$ 14.7 Candin-type antifungal agent Funguard 12.9 ⬇ 12.3 12.3 ⬇ 11.4 Oral quinolone antibiotic Geninax 12.3 ⬇ 11.7 11.7 $_{⬆}$ 12.4 OAB treatment Betanis 5.3 $_{⬆}$ 11.6 11.6 $_{⬆}$ 20.9 Treatment for adult patients with rheumatoid arthritis  Cimzia 0.1 $_{⬆}$ 3.2 3.2 $_{⬆}$ 12.3 Prostate cancer treatment Gonax 0.7 $_{⬆}$ 2.5 2.5 $_{⬆}$ 4.8 Sales of Major Products Micamlo BP (Hypertension treatment) Acofide (Functional dyspepsia treatment) Bisono Tape (Essential hypertension medication  (for mild to moderate cases)) Irribow OD (Diarrhea-predominant  irritable bowel syndrome treatment) Suglat (Type 2 diabetes treatment) XTANDI (Castration-resistant  prostate cancer treatment) 2013 May January June April September May 2014